Navigation Links
NeuroAiDTM, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke
Date:10/21/2013

SINGAPORE, Oct. 21, 2013 /PRNewswire/ -- NeuroAiD™, a treatment of post-stroke recovery containing natural extracts, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months after stroke onset, without an increase in bleeding rate and non-vascular deaths  according to research published online in the journal Stroke[1].  

The CHIMES study is an academic international double-blind placebo-controlled clinical trial in 1099 patients having suffered an ischemic stroke of intermediate severity within 72 hours, treated by NeuroAiD™ or placebo and monitored for 3 months.

Considering the positive effects of NeuroAiD™ on cerebral blood flow and a potential role in "ischemic preconditioning," CHIMES researchers hypothesized that NeuroAiD™ may have an effect on preventing the occurrence of early vascular events after stroke onset. They analyzed a composite outcome consisting of vascular events and vascular deaths, all events being blindly adjudicated. NeuroAiD™ was given on top of secondary prevention therapies like antiplatelet drugs, statins, and antihypertensive and antidiabetics treatments.

As a result the vascular outcome occurred in 16 patients (2.9%) of the NeuroAiD™ group, as opposed to 31 patients (5.6%) in the placebo group (p=0.025). This represents half the rate of early cardiovascular events and deaths, which corresponds to about 27 fewer patients suffering a recurrent vascular event or death per 1000 patients treated over 3 months. 

On the safety side, there was no increase in bleeding and non-vascular deaths, confirming the compound's excellent safety profile, with patients on NeuroAiD™ having fewer adverse events than those in the placebo group.

Prof Marie-Germaine Bousser, former Head of Neurology department in Hopital Lariboisiere in Paris and co-author of the publication, said this study revealed a potentially important effect of NeuroAiD™ in reducing morbidity and mortality after ischemic stroke. "Only a limited number of treatments have been shown to reduce early recurrent vascular events and deaths after acute stroke, mainly using antiplatelet agents and their combinations. NeuroAiD™ having no effect on platelet aggregation or coagulation could be added to these drugs without increasing bleeding risk."

Prof Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study, considers that pharmacological effects of NeuroAiD™ could explain the cardiovascular benefits observed in CHIMES trial. "NeuroAiD™ has been shown to increase cerebral blood flow velocity and to activate ATP-dependent potassium channels which play an important role in preconditioning, helping to improve tolerance of cerebral and myocardial tissues to ischemia. Further elucidate of other mechanisms of action of NeuroAiD™ in preventing vascular events would be very interesting."

This analysis was conducted by the CHIMES investigators, an international partnership of leaders in neurology, having carried out this large-scale trial to investigate the use of a product from natural substances in reducing disability and cardiovascular events after an acute stroke in a rigorous manner.

Occurring every 2 seconds, stroke is one of the leading causes of mortality and morbidity worldwide. Each year, 20 million people suffer from the devastating disease. There is an increasing need for multi-modal therapies to help more patients recover quickly and effectively from stroke, and to prevent recurrent cardiovascular events.

About CHIMES Society

The CHIMES Society is a unique international partnership which consists of an innovative academic industry collaboration with the objective to establish new stroke treatments. CHIMES is a Singaporean non-profit society founded by a group of experts in stroke and South-East Asian stroke clinicians interested to implement a research project: the NeuroAiD™ Efficacy on stroke recovery trial (CHIMES trial).

The CHIMES Study received a research grant from the National Medical Research Council in Singapore (NMRC) which supports the implementation of CHIMES trial in Singapore.

About Moleac

To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from Traditional Medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers' unaddressed needs. Moleac's neurorestorative drug NeuroAiD™ reaches patients in more than 30 countries.

[1]

Chen CLH et al. Effects of MLC601 on Early Vascular Events in Patients After Stroke: The CHIMES Study. Stroke 2013;44 published online before print October 17, 2013.


'/>"/>
SOURCE Chimes Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):